Bradley S. Fletcher

University of South Florida — United States

Medicine · Health Sciences

37h-index7.1kcitations108works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(24), Insect behavior and control techniques(21), Virus-based gene therapy research(9), Inflammatory mediators and NSAID effects(9), Estrogen and related hormone effects(9)

Publications106 total

Hemophilia prophylaxis: defining outcome measures by regulatory agencies and ISTH
Journal of Thrombosis and Haemostasis·2024
1764P Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
Annals of Oncology·2024
Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera
Journal of Clinical Medicine·2024· 4 citedOpen Access
Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S2 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S3 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S6 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Supplementary Methods and Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S3 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S1 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Supplementary Methods and Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S6 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
Figure S5 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
2023Open Access
A case study of 10 patients administered HBOC‐201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option
Transfusion·2020· 18 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Harvey R. Herschman(12), Dean A. Kujubu(6), E. T. Kapatos(6), Brian Varnum(5), Lucia Notterpek(5), Gary Visner(5), Arnold D. Heggestad(4), Hanzhong Liu(4), Li Liu(3), Robert W. Lim(2), Weilin Xie(2), Robert D. Andersen(2), Srinivasa T. Reddy(2), Ara M. Aslanian(2), Michael S. Kilberg(2), Sonia Sanz(2), Cathryn Mah(2), Jenny Fortun(2), Sara Pappas(2), Li Liu(2)